Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 24Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Squamous Cell 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 8Carboplatin 7Pemetrexed 5Nivolumab 5Cyclophosphamide 5Cisplatin 5ixazomib 4durvalumab 4Specimen Handling 4Paclitaxel 4Bevacizumab 4ibrutinib 3fludarabine phosphate 3fludarabine 3Ipilimumab 3Gemcitabine 3Docetaxel 3Cetuximab 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2temsirolimus 2evolocumab 2enzalutamide 2daratumumab 2atezolizumab 2Trastuzumab 2Tomography, X-Ray Computed 2Standard of Care 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × abemaciclib × 30 days × Clear all
NCT04169074 2026-05-22

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

University of Arizona

Phase 2 Terminated
7 enrolled 14 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡